TY - JOUR
T1 - In situ heart valve tissue engineering using a bioresorbable elastomeric implant - From material design to 12 months follow-up in sheep
AU - Kluin, Jolanda
AU - Talacua, Hanna
AU - Smits, Anthal I. P. M.
AU - Emmert, Maximilian Y.
AU - Brugmans, Marieke C. P.
AU - Fioretta, Emanuela S.
AU - Dijkman, Petra E.
AU - Söntjens, Serge H. M.
AU - Duijvelshoff, Renée
AU - Dekker, Sylvia
AU - Janssen-van den Broek, Marloes W. J. T.
AU - Lintas, Valentina
AU - Vink, Aryan
AU - Hoerstrup, Simon P.
AU - Janssen, Henk M.
AU - Dankers, Patricia Y. W.
AU - Baaijens, Frank P. T.
AU - Bouten, Carlijn V. C.
PY - 2017
Y1 - 2017
N2 - The creation of a living heart valve is a much-wanted alternative for current valve prostheses that suffer from limited durability and thromboembolic complications. Current strategies to create such valves, however, require the use of cells for in vitro culture, or decellularized human- or animal-derived donor tissue for in situ engineering. Here, we propose and demonstrate proof-of-concept of in situ heart valve tissue engineering using a synthetic approach, in which a cell-free, slow degrading elastomeric valvular implant is populated by endogenous cells to form new valvular tissue inside the heart. We designed a fibrous valvular scaffold, fabricated from a novel supramolecular elastomer, that enables endogenous cells to enter and produce matrix. Orthotopic implantations as pulmonary valve in sheep demonstrated sustained functionality up to 12 months, while the implant was gradually replaced by a layered collagen and elastic matrix in pace with cell-driven polymer resorption. Our results offer new perspectives for endogenous heart valve replacement starting from a readily-available synthetic graft that is compatible with surgical and transcatheter implantation procedures
AB - The creation of a living heart valve is a much-wanted alternative for current valve prostheses that suffer from limited durability and thromboembolic complications. Current strategies to create such valves, however, require the use of cells for in vitro culture, or decellularized human- or animal-derived donor tissue for in situ engineering. Here, we propose and demonstrate proof-of-concept of in situ heart valve tissue engineering using a synthetic approach, in which a cell-free, slow degrading elastomeric valvular implant is populated by endogenous cells to form new valvular tissue inside the heart. We designed a fibrous valvular scaffold, fabricated from a novel supramolecular elastomer, that enables endogenous cells to enter and produce matrix. Orthotopic implantations as pulmonary valve in sheep demonstrated sustained functionality up to 12 months, while the implant was gradually replaced by a layered collagen and elastic matrix in pace with cell-driven polymer resorption. Our results offer new perspectives for endogenous heart valve replacement starting from a readily-available synthetic graft that is compatible with surgical and transcatheter implantation procedures
U2 - https://doi.org/10.1016/j.biomaterials.2017.02.007
DO - https://doi.org/10.1016/j.biomaterials.2017.02.007
M3 - Article
C2 - 28253994
SN - 0142-9612
VL - 125
SP - 101
EP - 117
JO - Biomaterials
JF - Biomaterials
ER -